PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Linzagolix - Uterine fibroids

PAD Profile : Linzagolix - Uterine fibroids

Brand Names Include :
Yselty

Traffic Light Status

Status 1 of 1.

Status :
Blue
Important
Formulations :
  • Tablets
Important Information :
Specialist team initiation and at least a 1-month supply before requesting a transfer of prescribing to primary care.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
06 November 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves linzagolix for the treatment of moderate to severe symptoms of uterine fibroids as recommended by NICE TA996

Linzagolix for this indication will be considered as BLUE (following specialist initiation) on the traffic light system. Specialist will be expected to prescribe a minimum of 1 month of linzagolix before requesting transfer of care to the primary care prescriber.

Associated BNF Codes

06. Endocrine System
06.07.02. Drugs affecting gonadotrophins
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More